Welcome to our dedicated page for Clearmind Medici news (Ticker: CMND), a resource for investors and traders seeking the latest updates and insights on Clearmind Medici stock.
Clearmind Medicine Inc. (CMND) is a clinical-stage psychedelic pharmaceutical biotech company focused on developing novel neuroplastogen-derived and psychedelic-derived therapeutics, with a lead program targeting alcohol use disorder (AUD). The Clearmind news feed on Stock Titan highlights company announcements that trace the progress of its clinical pipeline, intellectual property strategy, and exchange listing status.
News items commonly cover key milestones in Clearmind’s FDA-approved Phase I/IIa clinical trial of CMND-100, its proprietary non-hallucinogenic MEAI-based oral candidate for AUD. These updates include cohort enrollment and completion, dosing at new clinical sites such as Yale School of Medicine, Johns Hopkins University, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center, and decisions by the independent Data and Safety Monitoring Board to allow the trial to continue following interim safety reviews.
Investors following CMND news will also see disclosures on peer-reviewed publications discussing MEAI’s pharmacological and receptor interaction profile, as well as articles that compare MEAI with other psychedelics and entactogens in the context of AUD. In addition, Clearmind regularly reports on capital markets developments, such as registered direct offerings, reverse share splits, and notifications from Nasdaq regarding compliance with minimum bid price and stockholders’ equity requirements.
This news page allows readers to track how Clearmind’s clinical-stage activities, patent portfolio expansion, and listing compliance efforts evolve over time. For anyone monitoring CMND stock or the broader field of psychedelic and neuroplastogen-based therapeutics for addiction and mental health, the Clearmind news stream provides a centralized view of the company’s publicly reported developments.
Clearmind Medicine (Nasdaq: CMND) will implement a 1-for-40 reverse share split effective December 15, 2025 to regain compliance with the Nasdaq Minimum Bid Price Rule. The board approved the reverse split on November 12, 2025. The reverse split will reduce the number of issued and outstanding common shares from 59,991,852 to 1,499,796, subject to fractional-share treatment.
No fractional common shares will be issued; instead, fractional shares will be rounded up to the nearest whole share. The company said authorized share capital remains unchanged and that outstanding options and warrants will be proportionately adjusted in quantity and per-share exercise price.
Clearmind Medicine (Nasdaq: CMND) received a Nasdaq notice on December 4, 2025, for noncompliance with the $1.00 minimum bid price requirement after the closing bid was below $1.00 for 30 consecutive business days.
Nasdaq granted a 180-calendar day compliance period through June 2, 2026 to regain compliance by achieving a $1.00 closing bid for at least 10 consecutive business days. The company shares will continue to be listed and traded under the symbol CMND during the period. If not compliant by June 2, 2026, the company may seek a second 180-day period only if it meets market value and other initial listing standards (except the bid-price rule). The company said it will monitor the closing bid and consider options to cure the deficiency, but provided no assurance it will regain compliance.
Clearmind Medicine (Nasdaq: CMND) announced the first participant was enrolled and dosed with CMND-100 at Hadassah-University Medical Center in Jerusalem on Dec. 2, 2025 as part of its multinational Phase I/IIa trial for Alcohol Use Disorder (AUD).
The trial evaluates safety, tolerability, pharmacokinetics and preliminary efficacy of the company’s MEAI-based oral candidate. Recent top-line results from the first cohort were described as positive and the Data and Safety Monitoring Board gave a unanimous recommendation to continue, supporting trial momentum across active sites.
Clearmind Medicine (Nasdaq: CMND) announced three clinical milestones for its MEAI-based oral therapy CMND-100 targeting Alcohol Use Disorder: positive top-line safety and preliminary efficacy data from the trial's first cohort of six participants (reported Nov 18, 2025); a unanimous independent DSMB recommendation to continue following an unblinded safety review (Nov 24, 2025); and activation of a new Israeli site, Tel Aviv Sourasky Medical Center, with first patient enrolled (Nov 25, 2025), joining Yale, Johns Hopkins and Hadassah sites. The Phase I/IIa trial evaluates safety, tolerability, pharmacokinetics and preliminary efficacy and the new site may accelerate multinational recruitment for subsequent phases.
Clearmind Medicine (Nasdaq: CMND) announced that Tel Aviv Sourasky Medical Center (TASMC) has enrolled the first patient in the company’s FDA-approved multinational Phase I/IIa trial of CMND-100 for Alcohol Use Disorder (AUD) on Nov 25, 2025. TASMC, led by Prof. David Zeltser, is now fully activated and joins sites including Yale, Johns Hopkins, and Hadassah.
The trial is assessing safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100, a non-hallucinogenic oral MEAI-based compound. Recent top-line data from the first completed cohort reported excellent safety and adherence with no serious adverse events. Management said TASMC enrollment accelerates global recruitment efforts.
Clearmind Medicine (Nasdaq: CMND) announced that its independent Data and Safety Monitoring Board completed an interim review of the FDA‑approved Phase I/IIa trial of CMND-100 for Alcohol Use Disorder on Nov 24, 2025 and unanimously recommended the trial continue.
Key interim findings from the initial dosing cohort included no serious adverse events, general good tolerability, and high adherence to the dosing regimen and study protocol. The multinational trial evaluates safety, tolerability, pharmacokinetics, and preliminary efficacy in reducing alcohol cravings and consumption.
Clearmind Medicine (Nasdaq: CMND) announced activation of Hadassah Medical Center as the fifth global site in its FDA‑approved Phase I/IIa trial of CMND‑100, a proprietary non‑hallucinogenic MEAI‑based oral candidate for Alcohol Use Disorder (AUD).
The multinational study evaluates safety, tolerability, pharmacokinetics and preliminary efficacy in moderate to severe AUD. Hadassah activated the site after final approval earlier in November 2025.
Top‑line data from the trial's first cohort reported a favorable safety profile with no serious adverse events and high participant adherence, supporting continued evaluation of CMND‑100.
Clearmind Medicine (NASDAQ: CMND) announced positive top-line results from the first cohort of its FDA-approved Phase I/IIa trial of CMND-100, a non-hallucinogenic MEAI-based oral candidate for Alcohol Use Disorder (AUD), on November 18, 2025. The six-patient first cohort showed a favorable safety profile with no serious adverse events reported and generally good tolerability. Investigators also reported high treatment adherence, supporting feasibility and patient acceptability. Dosing was completed at Johns Hopkins and Yale under the multicenter, single- and multiple-dose protocol; the company will continue evaluation in subsequent cohorts toward a full data readout.
Clearmind Medicine (Nasdaq: CMND) filed an Israeli patent application on Nov 17, 2025 for a novel combination therapy pairing MEAI (5-methoxy-2-aminoindane) with N-Acylethanolamines such as Palmitoylethanolamide (PEA) to address depression.
The filing arises from Clearmind's collaboration with Neurothera Labs and expands a portfolio that already includes 13 patents tied to MEAI–N-Acylethanolamine combinations for conditions including alcohol use disorder, cocaine addiction, obesity and depression. Clearmind said preclinical data support MEAI's efficacy in reducing addictive behaviors while preserving normal reward pathways.
Clearmind Medicine (Nasdaq: CMND) received final approval on Nov 13, 2025 for Hadassah Medical Center in Jerusalem to join its ongoing Phase 1/2a trial of CMND-100, an oral MEAI-based candidate for Alcohol Use Disorder (AUD).
The trial is multinational and multicenter, includes Yale, Johns Hopkins and Tel Aviv Sourasky, and has completed treatment of its first cohort. The study will assess safety, tolerability, pharmacokinetics and preliminary efficacy for reducing alcohol cravings and consumption. The company expects continued patient enrollment and data collection across sites.
FAQ
What is the current stock price of Clearmind Medici (CMND)?
What is the market cap of Clearmind Medici (CMND)?
